Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189)

    Summary
    EudraCT number
    2015-003694-15
    Trial protocol
    IE   DE   GB   AT   BE   ES   NL   FI   DK   FR  
    Global end of trial date
    22 Jun 2023

    Results information
    Results version number
    v1(current)
    This version publication date
    03 Jul 2024
    First version publication date
    03 Jul 2024
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    3475-189
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT02578680
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Merck Sharp & Dohme LLC
    Sponsor organisation address
    126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ, United States, 07065
    Public contact
    Clinical Trials Disclosure, Merck Sharp & Dohme LLC, ClinicalTrialsDisclosure@merck.com
    Scientific contact
    Clinical Trials Disclosure, Merck Sharp & Dohme LLC, ClinicalTrialsDisclosure@merck.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    22 Jun 2023
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    22 Jun 2023
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    This is an efficacy and safety study of pembrolizumab (MK-3475) combined with pemetrexed/platinum chemotherapy versus pemetrexed/platinum chemotherapy alone in participants with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have not previously received systemic therapy for advanced disease. Participants will be randomly assigned to receive pembrolizumab combined with pemetrexed/platinum (Investigators choice of cisplatin or carboplatin), OR pemetrexed/platinum (Investigators choice of cisplatin or carboplatin). The primary hypothesis is that pembrolizumab in combination with pemetrexed/platinum chemotherapy prolongs Progression-Free Survival (PFS) and Overall Survival (OS) compared to pemetrexed/platinum chemotherapy alone.
    Protection of trial subjects
    This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    15 Jan 2016
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Australia: 48
    Country: Number of subjects enrolled
    Austria: 29
    Country: Number of subjects enrolled
    Belgium: 10
    Country: Number of subjects enrolled
    Canada: 38
    Country: Number of subjects enrolled
    Denmark: 7
    Country: Number of subjects enrolled
    Finland: 4
    Country: Number of subjects enrolled
    France: 30
    Country: Number of subjects enrolled
    Germany: 65
    Country: Number of subjects enrolled
    Ireland: 11
    Country: Number of subjects enrolled
    Israel: 27
    Country: Number of subjects enrolled
    Italy: 58
    Country: Number of subjects enrolled
    Japan: 10
    Country: Number of subjects enrolled
    Netherlands: 9
    Country: Number of subjects enrolled
    Spain: 121
    Country: Number of subjects enrolled
    United Kingdom: 30
    Country: Number of subjects enrolled
    United States: 119
    Worldwide total number of subjects
    616
    EEA total number of subjects
    344
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    312
    From 65 to 84 years
    304
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    Eighty-four participants randomized to receive Control switched over to receive pembrolizumab monotherapy. Data from second course treatment contributed to safety data only. All primary and secondary outcome measures are based on protocol-specified cutoff (2017-11-08).

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Carer, Assessor

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Pembro+Pemetrexed+Platinum Chemo→Pembro+Pemetrexed
    Arm description
    Participants received pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. (Participants who received pembrolizumab 200 mg IV Q3W for up to 2 years but experienced disease progression, were eligible to receive a second course of pembrolizumab monotherapy 200 mg IV Q3W, at the investigator's discretion, for up to 1 additional year.)
    Arm type
    Experimental

    Investigational medicinal product name
    Pembrolizumab (Pembro)
    Investigational medicinal product code
    Other name
    KEYTRUDA®, MK-3475, SCH 9000475
    Pharmaceutical forms
    Concentrate and solvent for concentrate for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Pembrolizumab 200 mg IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV Q3W until progression.

    Investigational medicinal product name
    Cisplatin
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Cisplatin 75 mg/m^2 IV Day 1 of every 3-week cycle (Q3W) for 4 cycles

    Investigational medicinal product name
    Vitamin B12 1000 μg
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Vitamin B12 1000 μg intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.

    Investigational medicinal product name
    Pemetrexed
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Pemetrexed 500 mg/m^2 IV Q3W

    Investigational medicinal product name
    Folic acid 350-1000 μg
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    At least 5 doses of folic acid taken during the 7 days preceding the first dose of pemetrexed; folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed

    Investigational medicinal product name
    Dexamethasone 4 mg
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    For prophylaxis: dexamethasone 4 mg, orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.

    Investigational medicinal product name
    Carboplatin
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles

    Arm title
    Control
    Arm description
    Participants received saline placebo IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. (Effective 23-Dec-2019, participants discontinued saline placebo. If documented disease progression had occurred, and participants receiving Control met certain criteria, they were eligible to switch over to receive pembrolizumab monotherapy Q3W for the remainder of the study.)
    Arm type
    Active comparator

    Investigational medicinal product name
    Saline solution
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection/infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Saline placebo IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression.

    Investigational medicinal product name
    Cisplatin
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Cisplatin 75 mg/m^2 IV Day 1 of every 3-week cycle (Q3W) for 4 cycles

    Investigational medicinal product name
    Carboplatin
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles

    Investigational medicinal product name
    Dexamethasone 4 mg
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    For prophylaxis: dexamethasone 4 mg, orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.

    Investigational medicinal product name
    Folic acid 350-1000 μg
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    At least 5 doses of folic acid taken during the 7 days preceding the first dose of pemetrexed; folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed

    Investigational medicinal product name
    Vitamin B12 1000 μg
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Vitamin B12 1000 μg intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.

    Investigational medicinal product name
    Pemetrexed
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Pemetrexed 500 mg/m^2 IV Q3W

    Number of subjects in period 1
    Pembro+Pemetrexed+Platinum Chemo→Pembro+Pemetrexed Control
    Started
    410
    206
    Treated
    405
    202
    Switched to Pembrolizumab
    0
    84
    Completed
    0
    0
    Not completed
    410
    206
         Adverse event, serious fatal
    329
    181
         Consent withdrawn by subject
    13
    9
         Physician decision
    -
    1
         Sponsor Decision
    64
    13
         Lost to follow-up
    3
    1
         Protocol deviation
    1
    1

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Pembro+Pemetrexed+Platinum Chemo→Pembro+Pemetrexed
    Reporting group description
    Participants received pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. (Participants who received pembrolizumab 200 mg IV Q3W for up to 2 years but experienced disease progression, were eligible to receive a second course of pembrolizumab monotherapy 200 mg IV Q3W, at the investigator's discretion, for up to 1 additional year.)

    Reporting group title
    Control
    Reporting group description
    Participants received saline placebo IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. (Effective 23-Dec-2019, participants discontinued saline placebo. If documented disease progression had occurred, and participants receiving Control met certain criteria, they were eligible to switch over to receive pembrolizumab monotherapy Q3W for the remainder of the study.)

    Reporting group values
    Pembro+Pemetrexed+Platinum Chemo→Pembro+Pemetrexed Control Total
    Number of subjects
    410 206 616
    Age categorical
    Units: Subjects
    Age Continuous
    Units: Years
        arithmetic mean (standard deviation)
    63.2 ( 9.4 ) 62.8 ( 9.1 ) -
    Sex: Female, Male
    Units: Participants
        Female
    156 97 253
        Male
    254 109 363
    Programmed Cell Death-Ligand 1 (PD-L1) Tumor Status
    Participants were assessed for their PD-L1 tumor expression level by immunohistochemistry assay using tumor tissue from an archival or newly obtained biopsy. Participants with a TPS ≥1% were classified as PD-L1 positive and participants with a TPS <1% were classified as PD-L1 negative.
    Units: Subjects
        TPS <1%
    127 63 190
        TPS ≥1%
    260 128 388
        Not Evaluable
    23 15 38
    Platinum Chemotherapy
    Participants were classified according to the type of platinum chemotherapy the Investigator chose for them to receive: Cisplatin or Carboplatin.
    Units: Subjects
        Cisplatin
    113 58 171
        Carboplatin
    297 148 445
    Smoking Status
    Participants were classified according to their smoking status: Never Smoker or Former/Current Smoker.
    Units: Subjects
        Never Smoker
    48 25 73
        Former/Current Smoker
    362 181 543
    Race (NIH/OMB)
    Units: Subjects
        American Indian or Alaska Native
    0 0 0
        Asian
    10 8 18
        Native Hawaiian or Other Pacific Islander
    0 0 0
        Black or African American
    11 3 14
        White
    387 195 582
        More than one race
    0 0 0
        Unknown or Not Reported
    2 0 2

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Pembro+Pemetrexed+Platinum Chemo→Pembro+Pemetrexed
    Reporting group description
    Participants received pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. (Participants who received pembrolizumab 200 mg IV Q3W for up to 2 years but experienced disease progression, were eligible to receive a second course of pembrolizumab monotherapy 200 mg IV Q3W, at the investigator's discretion, for up to 1 additional year.)

    Reporting group title
    Control
    Reporting group description
    Participants received saline placebo IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. (Effective 23-Dec-2019, participants discontinued saline placebo. If documented disease progression had occurred, and participants receiving Control met certain criteria, they were eligible to switch over to receive pembrolizumab monotherapy Q3W for the remainder of the study.)

    Primary: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging (BCI)

    Close Top of page
    End point title
    Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging (BCI)
    End point description
    PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. The PFS per RECIST 1.1 is presented. The analysis population for this endpoint consisted of all randomized participants.
    End point type
    Primary
    End point timeframe
    Up to approximately 21 months
    End point values
    Pembro+Pemetrexed+Platinum Chemo→Pembro+Pemetrexed Control
    Number of subjects analysed
    410
    206
    Units: Months
        median (confidence interval 95%)
    8.8 (7.6 to 9.2)
    4.9 (4.7 to 5.5)
    Statistical analysis title
    PFS Per RECIST 1.1 as Assessed by BCI
    Comparison groups
    Pembro+Pemetrexed+Platinum Chemo→Pembro+Pemetrexed v Control
    Number of subjects included in analysis
    616
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    < 0.00001
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.52
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.43
         upper limit
    0.64

    Primary: Overall Survival (OS)

    Close Top of page
    End point title
    Overall Survival (OS)
    End point description
    OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the interim analysis were censored at the date of the last follow-up. The OS is presented. The analysis population for this endpoint consisted of all randomized participants. (Note: 99999=Median OS not reached; 99999=Lower Limit OS not reached; and 99999=Upper Limit OS not reached)
    End point type
    Primary
    End point timeframe
    Up to approximately 21 months
    End point values
    Pembro+Pemetrexed+Platinum Chemo→Pembro+Pemetrexed Control
    Number of subjects analysed
    410
    206
    Units: Months
        median (confidence interval 95%)
    99999 (99999 to 99999)
    11.3 (8.7 to 15.1)
    Statistical analysis title
    Overall Survival
    Comparison groups
    Pembro+Pemetrexed+Platinum Chemo→Pembro+Pemetrexed v Control
    Number of subjects included in analysis
    616
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    < 0.00001
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.49
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.38
         upper limit
    0.64

    Secondary: Overall Response Rate (ORR) Per RECIST 1.1 as Assessed by Blinded Central Imaging

    Close Top of page
    End point title
    Overall Response Rate (ORR) Per RECIST 1.1 as Assessed by Blinded Central Imaging
    End point description
    ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1. The percentage of participants who experienced a CR or PR is presented. The analysis population for this endpoint consisted of all randomized participants.
    End point type
    Secondary
    End point timeframe
    Up to approximately 21 months
    End point values
    Pembro+Pemetrexed+Platinum Chemo→Pembro+Pemetrexed Control
    Number of subjects analysed
    410
    206
    Units: Percentage of Participants
        number (confidence interval 95%)
    47.6 (42.6 to 52.5)
    18.9 (13.8 to 25.0)
    Statistical analysis title
    ORR Per RECIST 1.1 as Assessed by BCI
    Comparison groups
    Pembro+Pemetrexed+Platinum Chemo→Pembro+Pemetrexed v Control
    Number of subjects included in analysis
    616
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    < 0.0001 [1]
    Method
    Stratified Miettinen and Nurminen
    Parameter type
    Difference in Percentage vs. Control
    Point estimate
    28.5
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    21.1
         upper limit
    35.4
    Notes
    [1] - H0:Difference in percentages=0 vs H1:Difference in percentages>0

    Secondary: Number of Participants Who Discontinued Any Study Drug Due to an AE

    Close Top of page
    End point title
    Number of Participants Who Discontinued Any Study Drug Due to an AE
    End point description
    An AE was defined as any untoward medical occurrence in a study participant administered study drug and which does not necessarily have to have a causal relationship with this study drug. The number of participants who discontinued any randomized study drug due to an AE is presented. The analysis population consisted of all randomized participants who received ≥1 dose of study drug.
    End point type
    Secondary
    End point timeframe
    Up to approximately 21 months
    End point values
    Pembro+Pemetrexed+Platinum Chemo→Pembro+Pemetrexed Control
    Number of subjects analysed
    405
    202
    Units: Participants
    112
    30
    No statistical analyses for this end point

    Secondary: Number of Participants Who Experienced an Adverse Event (AE)

    Close Top of page
    End point title
    Number of Participants Who Experienced an Adverse Event (AE)
    End point description
    An AE was defined as any untoward medical occurrence in a study participant administered study drug and which does not necessarily have to have a causal relationship with this study drug. The number of participants who experienced an AE is presented. The analysis population consisted of all randomized participants who received ≥1 dose of study drug.
    End point type
    Secondary
    End point timeframe
    Up to approximately 21 months (Serious AEs: Up to 90 days after last dose of study treatment; Other AEs: Up to 30 days after last dose of study treatment)
    End point values
    Pembro+Pemetrexed+Platinum Chemo→Pembro+Pemetrexed Control
    Number of subjects analysed
    405
    202
    Units: Participants
    404
    200
    No statistical analyses for this end point

    Secondary: Duration of Response (DOR) Per RECIST 1.1 as Assessed by Blinded Central Imaging

    Close Top of page
    End point title
    Duration of Response (DOR) Per RECIST 1.1 as Assessed by Blinded Central Imaging
    End point description
    For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until PD or death. DOR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. DOR assessments were based on blinded central imaging review with confirmation. The DOR per RECIST 1.1 for all participants who experienced a confirmed CR or PR is presented. The analysis population consisted of all randomized participants who experienced a confirmed CR or confirmed PR.
    End point type
    Secondary
    End point timeframe
    Up to approximately 21 months
    End point values
    Pembro+Pemetrexed+Platinum Chemo→Pembro+Pemetrexed Control
    Number of subjects analysed
    195
    39
    Units: Months
        median (full range (min-max))
    11.2 (1.1 to 18.0)
    7.8 (2.1 to 16.4)
    No statistical analyses for this end point

    Other pre-specified: Progression-Free Survival (PFS) as Assessed by Investigator Immune-related RECIST (irRECIST) Response Criteria

    Close Top of page
    End point title
    Progression-Free Survival (PFS) as Assessed by Investigator Immune-related RECIST (irRECIST) Response Criteria
    End point description
    PFS was defined as the time from randomization to the first documented immune-related progressive disease (irPD) or death due to any cause, whichever occurred first. Per irRECIST, irPD was confirmed if any of the following are observed in 2 scans performed at least 4 weeks apart: target lesion sum of diameters remains ≥20 % and at least 5 mm absolute increase compared to nadir; non-target disease resulting in initial PD is qualitatively worse; new lesion resulting in initial irPD is qualitatively worse; additional new lesion(s) since last evaluation; or additional new non-target lesion progression since last evaluation. The PFS per irRECIST 1.1 is presented. The analysis population for this endpoint consisted of all randomized participants.
    End point type
    Other pre-specified
    End point timeframe
    Up to approximately 39 months
    End point values
    Pembro+Pemetrexed+Platinum Chemo→Pembro+Pemetrexed Control
    Number of subjects analysed
    410
    206
    Units: Months
        median (confidence interval 95%)
    10.3 (9.0 to 11.3)
    5.0 (4.8 to 6.0)
    Statistical analysis title
    PFS as Assessed by Invest irRECIST Rspns Crtra
    Comparison groups
    Pembro+Pemetrexed+Platinum Chemo→Pembro+Pemetrexed v Control
    Number of subjects included in analysis
    616
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    < 0.00001
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.49
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.41
         upper limit
    0.59

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Up to approximately 88 months
    Adverse event reporting additional description
    Safety Pop: Participants receiving ≥1 dose of study drug. Deaths (all causes) Pop: All randomized participants. Per protocol, progression of cancer was not considered an AE unless related to study drug. MedDRA preferred terms "Neoplasm progression", "Malignant neoplasm progression", "Disease progression" not related to study drug excluded as AEs.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    26.0
    Reporting groups
    Reporting group title
    Pembro+Pemetrexed+Platinum Chemo→Pembro+Pemetrexed
    Reporting group description
    Participants received pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. (Participants who received pembrolizumab 200 mg IV Q3W for up to 2 years but experienced disease progression, were eligible to receive a second course of pembrolizumab monotherapy 200 mg IV Q3W, at the investigator's discretion, for up to 1 additional year.)

    Reporting group title
    Control
    Reporting group description
    Participants received saline placebo IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. (Effective 23-Dec-2019, participants discontinued saline placebo. If documented disease progression had occurred, and participants receiving Control met certain criteria, they were eligible to switch over to receive pembrolizumab monotherapy Q3W for the remainder of the study.)

    Reporting group title
    Pembro+Pemetrexed+Platinum Chemo→Pembro+Pemetrexed, 2nd Course
    Reporting group description
    Participants who received pembrolizumab PLUS pemetrexed and platinum chemotherapy followed by pembrolizumab PLUS pemetrexed during the initial treatment but experienced disease progression, and met certain criteria, received a second course of pembrolizumab monotherapy at 200 mg IV Q3W for up to 1 additional year.

    Reporting group title
    Control Switched Over to Pembro Monotherapy, 2nd Course
    Reporting group description
    Participants who were switched from saline placebo to receive pembrolizumab monotherapy, and met certain criteria, received a second course of pembrolizumab monotherapy at 200 mg IV Q3W for up to 1 additional year.

    Reporting group title
    Control Switched Over to Pembro Monotherapy
    Reporting group description
    Qualified participants who received saline placebo with pemetrexed and platinum chemotherapy followed by placebo and pemetrexed, and who experienced disease progression, were switched over to receive pembrolizumab monotherapy 200 mg IV on Day 1 Q3W for up to 2 years.

    Serious adverse events
    Pembro+Pemetrexed+Platinum Chemo→Pembro+Pemetrexed Control Pembro+Pemetrexed+Platinum Chemo→Pembro+Pemetrexed, 2nd Course Control Switched Over to Pembro Monotherapy, 2nd Course Control Switched Over to Pembro Monotherapy
    Total subjects affected by serious adverse events
         subjects affected / exposed
    233 / 405 (57.53%)
    102 / 202 (50.50%)
    2 / 9 (22.22%)
    0 / 2 (0.00%)
    29 / 84 (34.52%)
         number of deaths (all causes)
    330
    113
    4
    1
    74
         number of deaths resulting from adverse events
    29
    14
    0
    0
    2
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Metastases to meninges
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metastases to central nervous system
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Prostate cancer
         subjects affected / exposed
    2 / 405 (0.49%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Adenocarcinoma of colon
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bladder cancer
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cancer pain
         subjects affected / exposed
    3 / 405 (0.74%)
    2 / 202 (0.99%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Malignant neoplasm progression
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tumour pain
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Thyroid cancer
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Squamous cell carcinoma
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Small cell lung cancer
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tracheal neoplasm
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vascular disorders
    Aortic stenosis
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypertension
         subjects affected / exposed
    2 / 405 (0.49%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Deep vein thrombosis
         subjects affected / exposed
    2 / 405 (0.49%)
    2 / 202 (0.99%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vena cava thrombosis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Peripheral artery occlusion
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Jugular vein thrombosis
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Venous occlusion
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Chest pain
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Asthenia
         subjects affected / exposed
    6 / 405 (1.48%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    3 / 6
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Death
         subjects affected / exposed
    3 / 405 (0.74%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 3
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    1 / 3
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    General physical health deterioration
         subjects affected / exposed
    6 / 405 (1.48%)
    2 / 202 (0.99%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    2 / 6
    2 / 3
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Fatigue
         subjects affected / exposed
    4 / 405 (0.99%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    3 / 4
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Inflammation
         subjects affected / exposed
    0 / 405 (0.00%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Mucosal inflammation
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Malaise
         subjects affected / exposed
    0 / 405 (0.00%)
    2 / 202 (0.99%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Localised oedema
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Influenza like illness
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pyrexia
         subjects affected / exposed
    9 / 405 (2.22%)
    5 / 202 (2.48%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    5 / 10
    1 / 5
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Oedema peripheral
         subjects affected / exposed
    2 / 405 (0.49%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Multiple organ dysfunction syndrome
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Immune system disorders
    Cytokine release syndrome
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Reproductive system and breast disorders
    Scrotal cyst
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Balanoposthitis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Chronic obstructive pulmonary disease
         subjects affected / exposed
    6 / 405 (1.48%)
    3 / 202 (1.49%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    1 / 8
    0 / 4
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Atelectasis
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Obstructive sleep apnoea syndrome
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pleural effusion
         subjects affected / exposed
    13 / 405 (3.21%)
    5 / 202 (2.48%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    2 / 14
    0 / 6
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonitis
         subjects affected / exposed
    13 / 405 (3.21%)
    5 / 202 (2.48%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    11 / 13
    3 / 5
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    2 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumothorax
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dyspnoea
         subjects affected / exposed
    6 / 405 (1.48%)
    3 / 202 (1.49%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    4 / 84 (4.76%)
         occurrences causally related to treatment / all
    0 / 6
    0 / 3
    0 / 0
    0 / 0
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    Epistaxis
         subjects affected / exposed
    1 / 405 (0.25%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemoptysis
         subjects affected / exposed
    3 / 405 (0.74%)
    2 / 202 (0.99%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Haemothorax
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hiccups
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Obstructive airways disorder
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary embolism
         subjects affected / exposed
    5 / 405 (1.23%)
    4 / 202 (1.98%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    3 / 84 (3.57%)
         occurrences causally related to treatment / all
    0 / 5
    1 / 4
    0 / 0
    0 / 0
    1 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    Pulmonary fibrosis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary haemorrhage
         subjects affected / exposed
    0 / 405 (0.00%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory failure
         subjects affected / exposed
    1 / 405 (0.25%)
    4 / 202 (1.98%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 4
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    Psychiatric disorders
    Confusional state
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Anxiety
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Major depression
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Disorientation
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Depression
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Delirium
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Product issues
    Device dislocation
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    1 / 405 (0.25%)
    2 / 202 (0.99%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    2 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood calcium decreased
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood magnesium decreased
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    C-reactive protein increased
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatic enzyme increased
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Platelet count decreased
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Hip fracture
         subjects affected / exposed
    2 / 405 (0.49%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Femur fracture
         subjects affected / exposed
    1 / 405 (0.25%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Femoral neck fracture
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Fall
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dislocation of vertebra
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Craniocerebral injury
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Accidental overdose
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Shoulder fracture
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Spinal compression fracture
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Spinal fracture
         subjects affected / exposed
    2 / 405 (0.49%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Toxicity to various agents
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Upper limb fracture
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Post procedural diarrhoea
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lumbar vertebral fracture
         subjects affected / exposed
    0 / 405 (0.00%)
    2 / 202 (0.99%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Limb traumatic amputation
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Radiation oesophagitis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Wrist fracture
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    Atrial fibrillation
         subjects affected / exposed
    1 / 405 (0.25%)
    3 / 202 (1.49%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 3
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Acute myocardial infarction
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Atrial flutter
         subjects affected / exposed
    0 / 405 (0.00%)
    2 / 202 (0.99%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiopulmonary failure
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac failure
         subjects affected / exposed
    4 / 405 (0.99%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 4
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac arrest
         subjects affected / exposed
    2 / 405 (0.49%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Left ventricular dysfunction
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Myopericarditis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Myocardial infarction
         subjects affected / exposed
    3 / 405 (0.74%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pericardial effusion
         subjects affected / exposed
    1 / 405 (0.25%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pericarditis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sinus tachycardia
         subjects affected / exposed
    3 / 405 (0.74%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Stress cardiomyopathy
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Supraventricular tachycardia
         subjects affected / exposed
    1 / 405 (0.25%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Ventricular arrhythmia
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Central nervous system vasculitis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Brain stem infarction
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Balance disorder
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebral haemorrhage
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Intracranial aneurysm
         subjects affected / exposed
    0 / 405 (0.00%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hydrocephalus
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hemiparesis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemorrhage intracranial
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Encephalopathy
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dizziness
         subjects affected / exposed
    4 / 405 (0.99%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Demyelinating polyneuropathy
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebrovascular accident
         subjects affected / exposed
    4 / 405 (0.99%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebral infarction
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ischaemic stroke
         subjects affected / exposed
    2 / 405 (0.49%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Seizure
         subjects affected / exposed
    2 / 405 (0.49%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Partial seizures
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lumbar radiculopathy
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lacunar stroke
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Syncope
         subjects affected / exposed
    3 / 405 (0.74%)
    2 / 202 (0.99%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Transient ischaemic attack
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Spinal cord compression
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Lymphadenopathy
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Leukopenia
         subjects affected / exposed
    3 / 405 (0.74%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    3 / 3
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Anaemia
         subjects affected / exposed
    13 / 405 (3.21%)
    11 / 202 (5.45%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    10 / 14
    11 / 12
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Disseminated intravascular coagulation
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Febrile neutropenia
         subjects affected / exposed
    25 / 405 (6.17%)
    4 / 202 (1.98%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    24 / 26
    4 / 4
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Thrombocytopenia
         subjects affected / exposed
    13 / 405 (3.21%)
    6 / 202 (2.97%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    14 / 14
    6 / 6
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pancytopenia
         subjects affected / exposed
    4 / 405 (0.99%)
    2 / 202 (0.99%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    4 / 4
    2 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neutropenia
         subjects affected / exposed
    11 / 405 (2.72%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    8 / 11
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Abdominal adhesions
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Abdominal pain upper
         subjects affected / exposed
    1 / 405 (0.25%)
    2 / 202 (0.99%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Abdominal pain
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Colitis
         subjects affected / exposed
    5 / 405 (1.23%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    5 / 5
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal perforation
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastritis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Duodenitis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diarrhoea
         subjects affected / exposed
    14 / 405 (3.46%)
    5 / 202 (2.48%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    13 / 16
    5 / 8
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Colitis ulcerative
         subjects affected / exposed
    0 / 405 (0.00%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Constipation
         subjects affected / exposed
    3 / 405 (0.74%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    2 / 84 (2.38%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 0
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lip oedema
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intussusception
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intestinal pseudo-obstruction
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intestinal ischaemia
         subjects affected / exposed
    2 / 405 (0.49%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Impaired gastric emptying
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Melaena
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal toxicity
         subjects affected / exposed
    0 / 405 (0.00%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Mesenteric artery embolism
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pancreatitis acute
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pancreatitis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Oesophagitis
         subjects affected / exposed
    1 / 405 (0.25%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Oesophageal stenosis
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neutropenic colitis
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nausea
         subjects affected / exposed
    5 / 405 (1.23%)
    7 / 202 (3.47%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    4 / 5
    3 / 7
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vomiting
         subjects affected / exposed
    7 / 405 (1.73%)
    5 / 202 (2.48%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    5 / 8
    4 / 5
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Stomatitis
         subjects affected / exposed
    1 / 405 (0.25%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    1 / 1
    1 / 1
    0 / 0
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Small intestinal haemorrhage
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pancreatitis chronic
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Bile duct stone
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Autoimmune hepatitis
         subjects affected / exposed
    2 / 405 (0.49%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cholangitis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cholangitis sclerosing
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Immune-mediated hepatitis
         subjects affected / exposed
    2 / 405 (0.49%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatitis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatic pain
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cholecystitis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    Stasis dermatitis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skin sensitisation
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rash papular
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rash
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dermatitis
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    Acute kidney injury
         subjects affected / exposed
    11 / 405 (2.72%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    8 / 11
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    2 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nephritis
         subjects affected / exposed
    2 / 405 (0.49%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haematuria
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Chronic kidney disease
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Autoimmune nephritis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Prerenal failure
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal failure
         subjects affected / exposed
    1 / 405 (0.25%)
    2 / 202 (0.99%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    1 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Renal tubular necrosis
         subjects affected / exposed
    1 / 405 (0.25%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tubulointerstitial nephritis
         subjects affected / exposed
    3 / 405 (0.74%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    3 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary tract obstruction
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary retention
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Endocrine disorders
    Adrenal insufficiency
         subjects affected / exposed
    1 / 405 (0.25%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypothyroidism
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    2 / 405 (0.49%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Back pain
         subjects affected / exposed
    1 / 405 (0.25%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neck pain
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Myalgia
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal chest pain
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Osteolysis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypertrophic osteoarthropathy
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haematoma muscle
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Groin pain
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Flank pain
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Muscular weakness
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Osteonecrosis of jaw
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pain in extremity
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pathological fracture
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Abdominal sepsis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bacteraemia
         subjects affected / exposed
    2 / 405 (0.49%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bacillus bacteraemia
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Arthritis bacterial
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Appendicitis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bacterial colitis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bronchitis
         subjects affected / exposed
    4 / 405 (0.99%)
    3 / 202 (1.49%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 4
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    CNS ventriculitis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    COVID-19 pneumonia
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diverticulitis
         subjects affected / exposed
    1 / 405 (0.25%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Clostridium difficile colitis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Clostridium difficile infection
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diabetic foot infection
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cellulitis
         subjects affected / exposed
    5 / 405 (1.23%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    5 / 6
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Erysipelas
         subjects affected / exposed
    2 / 405 (0.49%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Folliculitis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis
         subjects affected / exposed
    3 / 405 (0.74%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Herpes zoster
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infected dermal cyst
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infection
         subjects affected / exposed
    2 / 405 (0.49%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Empyema
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Encephalitis
         subjects affected / exposed
    2 / 405 (0.49%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Endocarditis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Enteritis infectious
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lower respiratory tract infection
         subjects affected / exposed
    4 / 405 (0.99%)
    4 / 202 (1.98%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    1 / 4
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Kidney infection
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Otitis media
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Oral candidiasis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neutropenic sepsis
         subjects affected / exposed
    2 / 405 (0.49%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lung abscess
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infectious pleural effusion
         subjects affected / exposed
    2 / 405 (0.49%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infective exacerbation of chronic obstructive airways disease
         subjects affected / exposed
    0 / 405 (0.00%)
    0 / 202 (0.00%)
    2 / 9 (22.22%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Influenza
         subjects affected / exposed
    3 / 405 (0.74%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    1 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Parotitis
         subjects affected / exposed
    0 / 405 (0.00%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia influenzal
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia bacterial
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia aspiration
         subjects affected / exposed
    2 / 405 (0.49%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia viral
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumocystis jirovecii pneumonia
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumococcal sepsis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Peritonitis
         subjects affected / exposed
    2 / 405 (0.49%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    34 / 405 (8.40%)
    18 / 202 (8.91%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    4 / 84 (4.76%)
         occurrences causally related to treatment / all
    6 / 35
    2 / 21
    0 / 0
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    1 / 3
    1 / 2
    0 / 0
    0 / 0
    0 / 0
    Salmonella bacteraemia
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory tract infection
         subjects affected / exposed
    2 / 405 (0.49%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory syncytial virus infection
         subjects affected / exposed
    0 / 405 (0.00%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pyelonephritis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary sepsis
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    7 / 405 (1.73%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    2 / 7
    0 / 1
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Upper respiratory tract infection
         subjects affected / exposed
    6 / 405 (1.48%)
    2 / 202 (0.99%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    1 / 6
    0 / 5
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tuberculous pleurisy
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tuberculosis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Septic shock
         subjects affected / exposed
    1 / 405 (0.25%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    Upper respiratory tract infection bacterial
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    5 / 405 (1.23%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 1
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urosepsis
         subjects affected / exposed
    2 / 405 (0.49%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    0 / 405 (0.00%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dehydration
         subjects affected / exposed
    5 / 405 (1.23%)
    2 / 202 (0.99%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    3 / 7
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diabetes mellitus inadequate control
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypercalcaemia
         subjects affected / exposed
    0 / 405 (0.00%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Type 2 diabetes mellitus
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Type 1 diabetes mellitus
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Polydipsia
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Malnutrition
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hyponatraemia
         subjects affected / exposed
    2 / 405 (0.49%)
    2 / 202 (0.99%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypomagnesaemia
         subjects affected / exposed
    2 / 405 (0.49%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypokalaemia
         subjects affected / exposed
    1 / 405 (0.25%)
    1 / 202 (0.50%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Pembro+Pemetrexed+Platinum Chemo→Pembro+Pemetrexed Control Pembro+Pemetrexed+Platinum Chemo→Pembro+Pemetrexed, 2nd Course Control Switched Over to Pembro Monotherapy, 2nd Course Control Switched Over to Pembro Monotherapy
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    395 / 405 (97.53%)
    196 / 202 (97.03%)
    9 / 9 (100.00%)
    2 / 2 (100.00%)
    64 / 84 (76.19%)
    Vascular disorders
    Hypertension
         subjects affected / exposed
    23 / 405 (5.68%)
    11 / 202 (5.45%)
    2 / 9 (22.22%)
    0 / 2 (0.00%)
    5 / 84 (5.95%)
         occurrences all number
    25
    14
    2
    0
    6
    Hypotension
         subjects affected / exposed
    24 / 405 (5.93%)
    4 / 202 (1.98%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences all number
    27
    4
    0
    0
    1
    General disorders and administration site conditions
    Mucosal inflammation
         subjects affected / exposed
    37 / 405 (9.14%)
    16 / 202 (7.92%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences all number
    48
    24
    0
    0
    1
    Fatigue
         subjects affected / exposed
    173 / 405 (42.72%)
    80 / 202 (39.60%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    8 / 84 (9.52%)
         occurrences all number
    285
    127
    1
    0
    9
    Chest pain
         subjects affected / exposed
    38 / 405 (9.38%)
    12 / 202 (5.94%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    6 / 84 (7.14%)
         occurrences all number
    44
    14
    0
    0
    6
    Asthenia
         subjects affected / exposed
    85 / 405 (20.99%)
    47 / 202 (23.27%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    6 / 84 (7.14%)
         occurrences all number
    158
    74
    0
    0
    8
    Oedema peripheral
         subjects affected / exposed
    103 / 405 (25.43%)
    35 / 202 (17.33%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    11 / 84 (13.10%)
         occurrences all number
    180
    48
    0
    0
    11
    Pain
         subjects affected / exposed
    22 / 405 (5.43%)
    7 / 202 (3.47%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences all number
    22
    7
    0
    0
    1
    Pyrexia
         subjects affected / exposed
    84 / 405 (20.74%)
    30 / 202 (14.85%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    6 / 84 (7.14%)
         occurrences all number
    118
    47
    0
    0
    7
    Respiratory, thoracic and mediastinal disorders
    Oropharyngeal pain
         subjects affected / exposed
    27 / 405 (6.67%)
    6 / 202 (2.97%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences all number
    33
    6
    0
    0
    1
    Dyspnoea
         subjects affected / exposed
    97 / 405 (23.95%)
    51 / 202 (25.25%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    15 / 84 (17.86%)
         occurrences all number
    118
    59
    1
    0
    20
    Epistaxis
         subjects affected / exposed
    29 / 405 (7.16%)
    7 / 202 (3.47%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences all number
    35
    11
    0
    0
    0
    Haemoptysis
         subjects affected / exposed
    14 / 405 (3.46%)
    16 / 202 (7.92%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    2 / 84 (2.38%)
         occurrences all number
    16
    20
    0
    0
    2
    Cough
         subjects affected / exposed
    104 / 405 (25.68%)
    62 / 202 (30.69%)
    2 / 9 (22.22%)
    0 / 2 (0.00%)
    9 / 84 (10.71%)
         occurrences all number
    139
    71
    2
    0
    13
    Productive cough
         subjects affected / exposed
    27 / 405 (6.67%)
    9 / 202 (4.46%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    3 / 84 (3.57%)
         occurrences all number
    33
    10
    1
    0
    4
    Rhinorrhoea
         subjects affected / exposed
    25 / 405 (6.17%)
    10 / 202 (4.95%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences all number
    28
    10
    1
    0
    1
    Wheezing
         subjects affected / exposed
    10 / 405 (2.47%)
    2 / 202 (0.99%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences all number
    11
    2
    1
    0
    1
    Psychiatric disorders
    Insomnia
         subjects affected / exposed
    31 / 405 (7.65%)
    17 / 202 (8.42%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences all number
    35
    17
    1
    0
    1
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    50 / 405 (12.35%)
    19 / 202 (9.41%)
    0 / 9 (0.00%)
    1 / 2 (50.00%)
    4 / 84 (4.76%)
         occurrences all number
    63
    23
    0
    1
    4
    Aspartate aminotransferase increased
         subjects affected / exposed
    40 / 405 (9.88%)
    13 / 202 (6.44%)
    0 / 9 (0.00%)
    1 / 2 (50.00%)
    5 / 84 (5.95%)
         occurrences all number
    57
    16
    0
    2
    6
    Blood alkaline phosphatase increased
         subjects affected / exposed
    16 / 405 (3.95%)
    9 / 202 (4.46%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    2 / 84 (2.38%)
         occurrences all number
    21
    11
    1
    0
    2
    Blood bilirubin increased
         subjects affected / exposed
    1 / 405 (0.25%)
    2 / 202 (0.99%)
    0 / 9 (0.00%)
    1 / 2 (50.00%)
    0 / 84 (0.00%)
         occurrences all number
    1
    2
    0
    1
    0
    Weight decreased
         subjects affected / exposed
    44 / 405 (10.86%)
    16 / 202 (7.92%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    4 / 84 (4.76%)
         occurrences all number
    59
    17
    0
    0
    4
    Tri-iodothyronine increased
         subjects affected / exposed
    0 / 405 (0.00%)
    0 / 202 (0.00%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    Blood magnesium decreased
         subjects affected / exposed
    4 / 405 (0.99%)
    4 / 202 (1.98%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences all number
    4
    4
    1
    0
    0
    Blood creatinine increased
         subjects affected / exposed
    58 / 405 (14.32%)
    17 / 202 (8.42%)
    0 / 9 (0.00%)
    1 / 2 (50.00%)
    4 / 84 (4.76%)
         occurrences all number
    97
    29
    0
    1
    10
    White blood cell count decreased
         subjects affected / exposed
    28 / 405 (6.91%)
    13 / 202 (6.44%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences all number
    57
    20
    0
    0
    0
    Injury, poisoning and procedural complications
    Contusion
         subjects affected / exposed
    6 / 405 (1.48%)
    1 / 202 (0.50%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences all number
    6
    1
    2
    0
    0
    Skin abrasion
         subjects affected / exposed
    1 / 405 (0.25%)
    2 / 202 (0.99%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences all number
    1
    2
    1
    0
    0
    Nervous system disorders
    Dysgeusia
         subjects affected / exposed
    36 / 405 (8.89%)
    17 / 202 (8.42%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences all number
    41
    17
    0
    0
    1
    Dizziness
         subjects affected / exposed
    58 / 405 (14.32%)
    22 / 202 (10.89%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    2 / 84 (2.38%)
         occurrences all number
    64
    27
    0
    0
    2
    Headache
         subjects affected / exposed
    57 / 405 (14.07%)
    22 / 202 (10.89%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    5 / 84 (5.95%)
         occurrences all number
    72
    29
    0
    0
    7
    Paraesthesia
         subjects affected / exposed
    24 / 405 (5.93%)
    14 / 202 (6.93%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences all number
    33
    21
    0
    0
    1
    Radiculopathy
         subjects affected / exposed
    0 / 405 (0.00%)
    0 / 202 (0.00%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    Blood and lymphatic system disorders
    Leukopenia
         subjects affected / exposed
    26 / 405 (6.42%)
    13 / 202 (6.44%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences all number
    44
    18
    0
    0
    0
    Neutropenia
         subjects affected / exposed
    108 / 405 (26.67%)
    49 / 202 (24.26%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences all number
    213
    92
    0
    0
    0
    Anaemia
         subjects affected / exposed
    186 / 405 (45.93%)
    91 / 202 (45.05%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    6 / 84 (7.14%)
         occurrences all number
    253
    114
    0
    0
    8
    Thrombocytopenia
         subjects affected / exposed
    68 / 405 (16.79%)
    25 / 202 (12.38%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences all number
    108
    37
    0
    0
    1
    Ear and labyrinth disorders
    Vertigo
         subjects affected / exposed
    17 / 405 (4.20%)
    4 / 202 (1.98%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences all number
    21
    7
    1
    0
    2
    Otorrhoea
         subjects affected / exposed
    0 / 405 (0.00%)
    0 / 202 (0.00%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    Ear discomfort
         subjects affected / exposed
    3 / 405 (0.74%)
    1 / 202 (0.50%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences all number
    3
    1
    1
    0
    0
    Tinnitus
         subjects affected / exposed
    14 / 405 (3.46%)
    11 / 202 (5.45%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences all number
    19
    12
    0
    0
    0
    Eye disorders
    Dry eye
         subjects affected / exposed
    21 / 405 (5.19%)
    5 / 202 (2.48%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    2 / 84 (2.38%)
         occurrences all number
    23
    5
    0
    0
    2
    Lacrimation increased
         subjects affected / exposed
    75 / 405 (18.52%)
    22 / 202 (10.89%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences all number
    87
    24
    0
    0
    1
    Gastrointestinal disorders
    Constipation
         subjects affected / exposed
    143 / 405 (35.31%)
    67 / 202 (33.17%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    7 / 84 (8.33%)
         occurrences all number
    220
    87
    0
    0
    7
    Abdominal pain
         subjects affected / exposed
    39 / 405 (9.63%)
    13 / 202 (6.44%)
    2 / 9 (22.22%)
    0 / 2 (0.00%)
    7 / 84 (8.33%)
         occurrences all number
    49
    14
    2
    0
    7
    Abdominal pain upper
         subjects affected / exposed
    29 / 405 (7.16%)
    4 / 202 (1.98%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences all number
    31
    4
    0
    0
    0
    Dyspepsia
         subjects affected / exposed
    28 / 405 (6.91%)
    11 / 202 (5.45%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences all number
    31
    11
    0
    0
    1
    Diarrhoea
         subjects affected / exposed
    123 / 405 (30.37%)
    41 / 202 (20.30%)
    2 / 9 (22.22%)
    0 / 2 (0.00%)
    11 / 84 (13.10%)
         occurrences all number
    179
    54
    2
    0
    19
    Gastrooesophageal reflux disease
         subjects affected / exposed
    17 / 405 (4.20%)
    6 / 202 (2.97%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    2 / 84 (2.38%)
         occurrences all number
    18
    6
    1
    0
    2
    Vomiting
         subjects affected / exposed
    104 / 405 (25.68%)
    43 / 202 (21.29%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    12 / 84 (14.29%)
         occurrences all number
    183
    70
    2
    0
    14
    Stomatitis
         subjects affected / exposed
    37 / 405 (9.14%)
    16 / 202 (7.92%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences all number
    54
    21
    0
    0
    0
    Nausea
         subjects affected / exposed
    232 / 405 (57.28%)
    103 / 202 (50.99%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    16 / 84 (19.05%)
         occurrences all number
    430
    186
    2
    0
    18
    Skin and subcutaneous tissue disorders
    Skin ulcer
         subjects affected / exposed
    2 / 405 (0.49%)
    2 / 202 (0.99%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences all number
    2
    2
    1
    0
    0
    Alopecia
         subjects affected / exposed
    22 / 405 (5.43%)
    10 / 202 (4.95%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences all number
    24
    10
    0
    0
    0
    Dry skin
         subjects affected / exposed
    27 / 405 (6.67%)
    20 / 202 (9.90%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences all number
    28
    22
    1
    0
    1
    Erythema
         subjects affected / exposed
    30 / 405 (7.41%)
    4 / 202 (1.98%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    3 / 84 (3.57%)
         occurrences all number
    38
    5
    0
    0
    3
    Pruritus
         subjects affected / exposed
    59 / 405 (14.57%)
    23 / 202 (11.39%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    4 / 84 (4.76%)
         occurrences all number
    80
    25
    1
    0
    4
    Rash
         subjects affected / exposed
    89 / 405 (21.98%)
    27 / 202 (13.37%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    4 / 84 (4.76%)
         occurrences all number
    131
    36
    0
    0
    4
    Renal and urinary disorders
    Proteinuria
         subjects affected / exposed
    4 / 405 (0.99%)
    0 / 202 (0.00%)
    2 / 9 (22.22%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences all number
    4
    0
    3
    0
    0
    Endocrine disorders
    Hypothyroidism
         subjects affected / exposed
    31 / 405 (7.65%)
    5 / 202 (2.48%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    6 / 84 (7.14%)
         occurrences all number
    38
    7
    0
    0
    6
    Musculoskeletal and connective tissue disorders
    Pain in extremity
         subjects affected / exposed
    37 / 405 (9.14%)
    18 / 202 (8.91%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    6 / 84 (7.14%)
         occurrences all number
    47
    18
    1
    0
    7
    Osteoarthritis
         subjects affected / exposed
    1 / 405 (0.25%)
    0 / 202 (0.00%)
    0 / 9 (0.00%)
    1 / 2 (50.00%)
    0 / 84 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    Neck pain
         subjects affected / exposed
    16 / 405 (3.95%)
    6 / 202 (2.97%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    4 / 84 (4.76%)
         occurrences all number
    16
    8
    1
    0
    4
    Musculoskeletal pain
         subjects affected / exposed
    10 / 405 (2.47%)
    8 / 202 (3.96%)
    0 / 9 (0.00%)
    1 / 2 (50.00%)
    1 / 84 (1.19%)
         occurrences all number
    13
    9
    0
    1
    1
    Musculoskeletal chest pain
         subjects affected / exposed
    19 / 405 (4.69%)
    7 / 202 (3.47%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    2 / 84 (2.38%)
         occurrences all number
    23
    7
    1
    0
    2
    Back pain
         subjects affected / exposed
    71 / 405 (17.53%)
    26 / 202 (12.87%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    7 / 84 (8.33%)
         occurrences all number
    86
    29
    0
    0
    7
    Arthralgia
         subjects affected / exposed
    70 / 405 (17.28%)
    28 / 202 (13.86%)
    1 / 9 (11.11%)
    1 / 2 (50.00%)
    10 / 84 (11.90%)
         occurrences all number
    99
    33
    1
    1
    12
    Infections and infestations
    Otitis externa
         subjects affected / exposed
    0 / 405 (0.00%)
    0 / 202 (0.00%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    Nasopharyngitis
         subjects affected / exposed
    47 / 405 (11.60%)
    10 / 202 (4.95%)
    2 / 9 (22.22%)
    0 / 2 (0.00%)
    5 / 84 (5.95%)
         occurrences all number
    76
    12
    2
    0
    6
    Pneumonia
         subjects affected / exposed
    21 / 405 (5.19%)
    6 / 202 (2.97%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    2 / 84 (2.38%)
         occurrences all number
    29
    6
    0
    0
    2
    Ear infection
         subjects affected / exposed
    2 / 405 (0.49%)
    0 / 202 (0.00%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences all number
    2
    0
    1
    0
    0
    Conjunctivitis
         subjects affected / exposed
    37 / 405 (9.14%)
    18 / 202 (8.91%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences all number
    48
    33
    0
    0
    0
    Bronchitis
         subjects affected / exposed
    23 / 405 (5.68%)
    6 / 202 (2.97%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    2 / 84 (2.38%)
         occurrences all number
    29
    7
    0
    0
    2
    Herpes zoster
         subjects affected / exposed
    11 / 405 (2.72%)
    2 / 202 (0.99%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    2 / 84 (2.38%)
         occurrences all number
    12
    2
    1
    0
    2
    Sinusitis
         subjects affected / exposed
    10 / 405 (2.47%)
    1 / 202 (0.50%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    2 / 84 (2.38%)
         occurrences all number
    12
    1
    1
    0
    3
    Upper respiratory tract infection
         subjects affected / exposed
    44 / 405 (10.86%)
    16 / 202 (7.92%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences all number
    59
    17
    1
    0
    1
    Urinary tract infection
         subjects affected / exposed
    34 / 405 (8.40%)
    13 / 202 (6.44%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    4 / 84 (4.76%)
         occurrences all number
    47
    17
    0
    0
    6
    Metabolism and nutrition disorders
    Hypomagnesaemia
         subjects affected / exposed
    37 / 405 (9.14%)
    8 / 202 (3.96%)
    1 / 9 (11.11%)
    0 / 2 (0.00%)
    0 / 84 (0.00%)
         occurrences all number
    54
    14
    1
    0
    0
    Hypokalaemia
         subjects affected / exposed
    51 / 405 (12.59%)
    16 / 202 (7.92%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    2 / 84 (2.38%)
         occurrences all number
    91
    20
    0
    0
    2
    Hyperglycaemia
         subjects affected / exposed
    34 / 405 (8.40%)
    7 / 202 (3.47%)
    0 / 9 (0.00%)
    1 / 2 (50.00%)
    2 / 84 (2.38%)
         occurrences all number
    49
    10
    0
    2
    2
    Decreased appetite
         subjects affected / exposed
    122 / 405 (30.12%)
    63 / 202 (31.19%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    17 / 84 (20.24%)
         occurrences all number
    172
    81
    0
    0
    19
    Hypophosphataemia
         subjects affected / exposed
    24 / 405 (5.93%)
    5 / 202 (2.48%)
    0 / 9 (0.00%)
    0 / 2 (0.00%)
    1 / 84 (1.19%)
         occurrences all number
    38
    13
    0
    0
    1

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    03 Mar 2016
    Amendment 02: The primary reason for this protocol amendment was to update the reporting period for all adverse events following cessation of treatment to 30 days.
    17 Mar 2017
    Amendment 04: The primary reason for this protocol amendment was to add an OS test at the second interim analysis and the final analysis to achieve at least 88% power; IA1 timing was changed to ~6 months after the last subject had been enrolled; FA would be performed after approximately 369 deaths had been observed.
    07 Dec 2017
    Amendment 07: The primary reason for this protocol amendment was to provide a more robust analysis of the data, focusing on OS, and to adjust the alpha spending to most inform the clinical meaningfulness of the data.
    29 Oct 2018
    Amendment 09: The primary reason for this protocol amendment was to discontinue pharmacokinetic (PK) and anti-drug antibodies (ADA) sampling and updated pembrolizumab dose justification language based on input from regulatory authorities.
    24 Feb 2020
    Amendment 10: The primary reasons for this protocol amendment were to state that final analysis results were positive and that therefore participants were to be given the option of discontinuing placebo treatment.
    16 Mar 2022
    Amendment 11: The primary reason for this protocol amendment was to add text to allow participants to rollover to extension study (MK-3475-587).

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 08:09:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA